Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1266P - Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma

Date

17 Sep 2020

Session

E-Poster Display

Presenters

Margarita Majem

Citation

Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283

Authors

M. Majem1, E. Felip2, B. Doger3, M. Akay4, E. Carcereny5, T. Clay6, M.G. Krebs7, J. Peguero8, F. Triebel9

Author affiliations

  • 1 Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, 08025 - Barcelona/ES
  • 2 Medical Oncology, Vall d’Hebron University Hospital, 8035 - Barcelona/ES
  • 3 Start Madrid-fjd, Fundación Jiménez Díaz, 28040 - Madrid/ES
  • 4 Oncology Department, University College London Hospital, W1T 7HA - London/GB
  • 5 Oncology Department, Institut Català d'Oncologia  Badalona-Hospital Germans Trias i Pujol, 08916 - Badalona/ES
  • 6 Oncology Department, St John of God Subiaco Hospital, 6008 - Perth/AU
  • 7 Division Of Cancer Sciences, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 8 Oncology Department, Oncology Consultants, 77030 - Houston/US
  • 9 Immunology, Immutep S.A.S. (Immutep), 91893 - Orsay/FR
More

Resources

Abstract 1266P

Background

Eftilagimod alpha (efti) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell (APC) activation and CD8 T-cell activation. The stimulation of the dendritic cell network and subsequent T cell recruitment with efti may lead to stronger anti-tumor responses in combination than observed with pembrolizumab alone. We hereby report initial results of the non-small cell lung cancer (NSCLC) part (NCT03625323).

Methods

The study has a Simon's 2-stage design, with objective response rate (ORR) as primary endpoint (EP). Secondary EPs include tolerability, disease control rate (DCR), progression free survival (PFS), PK, PD and immunogenicity. Treatment naïve PD-L1 unselected NSCLC patients (pts) are eligible for part A. Initially, 17 pts were recruited in stage 1, with an additional 19 pts enrolled into stage 2 if a pre-specified threshold is reached. Efti is administered as 30 mg SC injection every 2 wks for 8 cycles and then every 3 wks for 9 cycles with pembrolizumab (200 mg IV infusion every 3 wks for up to 2 yrs).

Results

Between Mar 2019 and May 2020 33 pts were enrolled into stages 1 + 2. The median age was 67 yrs (range 53-84) and 70 % were male. ECOG PS 0:1 was 42 % and 58 % respectively. Pts from all PD-L1 subgroups were recruited. Pts received a median of 5 pembrolizumab and 7 efti administrations. All pts in stage 1 (n=17) were evaluable. Nine pts (53 %) had a partial response (iPR) and five (29 %) had stable disease according to iRECIST representing an ORR (DCR) of 53 % (82 %). Responses were observed among all PD-L1 subgroups with 1/3 iPRs in <1%, 3/6 iPRs in 1-49 %, 3/4 iPRs in ≥50% and 2/4 in the NE group. The most common (> 10 %) adverse events (AEs) were cough (29 %), asthenia (24 %), decreased appetite (18 %), dyspnea (18 %), fatigue (17 %), diarrhea (15 %) and nausea (12 %). Seven (7; 41 %) pts are still on therapy and median PFS is not yet reached (follow-up of 9+ months). The threshold (r>4) for opening of stage 2 was reached and initial data for stage 2 pts will be presented at the meeting.

Conclusions

Efti in combination with pembrolizumab is safe and shows encouraging antitumor activity in 1st line NSCLC across all PD-L1 expression levels.

Clinical trial identification

EudraCT: 2018-001994-25, NCT03625323.

Editorial acknowledgement

Legal entity responsible for the study

Immutep S.A.S.

Funding

Immutep S.A.S.

Disclosure

M. Majem: Advisory/Consultancy: AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Helsinn Therapeutics; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda; Tesaro; Research grant/Funding (institution): BMS (Inst); Travel/Accommodation/Expenses: AstraZeneca; Roche. E. Felip: Advisory/Consultancy: AbbVie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; Medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; priME Oncology; Roche; Samsung; Takeda; Touchtime; Speaker Bureau/Expert testimony: AbbVie; AbbVie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Prime Oncology; Roche; Samsung; Takeda;; Research grant/Funding (institution): EMD Serono (Inst); FUNDACIÓN MERCK SALUD (Inst); Non-remunerated activity/ies, Other : GRÍFOLS. E. Carcereny: Advisory/Consultancy: AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda; ; Travel/Accommodation/Expenses: Roche, Takeda. T. Clay: Honoraria (self): AstraZeneca; Novartis; Roche; Speaker Bureau/Expert testimony: AstraZeneca; Novartis; Novarti; Research grant/Funding (institution): Bayer (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); Clovis Oncology (Inst); Exelixis (Inst); Immutep (Inst); Merck Sharp & Dohme (Inst); Travel/Accommodation/Expenses: Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Roche/Genentech. M.G. Krebs: Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Roche; Advisory/Consultancy: Achilles Therapeutics; Bayer; Janssen; Octimet; Roche; ; Travel/Accommodation/Expenses: AstraZeneca; BerGenBio; BerGenBio; Research grant/Funding (institution): BerGenBio (Inst). J. Peguero: Full/Part-time employment: Oncology Consultants, P.A.; Leadership role: Director, Research Department. F. Triebel: Full/Part-time employment: Immutep SAS; Shareholder/Stockholder/Stock options: Immutep Ltd; Licensing/Royalties: Being an inventor on patents on LAG-3 owned by Immutep SAS. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings